Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Subclinical Atheroma
NCT07803679Phase 4Not yet recruiting
- Sponsor
- Amgen
- Start
- Jan 2027
- Primary completion
- Apr 2029
01
Overview
Phase 4, randomised, open-label trial of evolocumab in coronary artery disease (CAD), hypercholesterolemia, Atheroma and 1 more (2 arms), sponsored by Amgen. Primary endpoint: Non-Calcified Plaque Volume at 72 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)hypercholesterolemiaAtheromaatherosclerosis
Beyond the preview
Go deeper on NCT07803679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803679.